López Estévez, Ana MaríaLapuhs, PhilippPiñeiro Alonso, LauraAlonso Fernández, María José2024-02-232024-02-232023A. M. López-Estévez, P. Lapuhs, L. Pineiro-Alonso, M. J. Alonso, Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals. Adv. Mater. 2023, 2309355. https://doi.org/10.1002/adma.2023093550935-9648http://hdl.handle.net/10347/32892The success of personalized medicine in oncology relies on using highlyeffective and precise therapeutic modalities such as small interfering RNA(siRNA) and monoclonal antibodies (mAbs). Unfortunately, the clinicalexploitation of these biological drugs has encountered obstacles inovercoming intricate biological barriers. Drug delivery technologies representa plausible strategy to overcome such barriers, ultimately facilitating theaccess to intracellular domains. Here, an overview of the current landscapeon how nanotechnology has dealt with protein corona phenomena as a firstand determinant biological barrier is presented. This continues with theanalysis of strategies facilitating access to the tumor, along with conceivablemethods for enhanced tumor penetration. As a final step, the cellular barriersthat nanocarriers must confront in order for their biological cargo to reachtheir target are deeply analyzed. This review concludes with a critical analysisand future perspectives of the translational advances in personalizedoncological nanomedicineeng© 2023 The Authors. Advanced Materials published by Wiley-VCHGmbH. This is an open access article under the terms of theCreativeCommons Attribution-NonCommercial-NoDerivsLicensehttp://creativecommons.org/licenses/by-nc-nd/4.0/CancerIntracellularMonoclonal antibodyNanotechnologyRNAjournal article10.1002/adma.2023093551521-4095open access